These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3108550)

  • 21. Prevalence of HTLV-III/LAV antibodies in patients with hemophilia and in their sexual partners in France.
    Allain JP
    N Engl J Med; 1986 Aug; 315(8):517-8. PubMed ID: 3016541
    [No Abstract]   [Full Text] [Related]  

  • 22. LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France.
    Mathez D; Leibovitch J; Sultan Y; Maisonneuve P
    N Engl J Med; 1986 Jan; 314(2):118-9. PubMed ID: 3079879
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunological profile of drug addicts: HTLV-III negative, HTLV-III positive and those with lymphadenopathy syndrome-AIDS related complex].
    Cascavilla N; Martini E; Melillo L; Musto P; Nobile M; Valori VM; Di Giorgio G; Carotenuto M
    Recenti Prog Med; 1987 Mar; 78(3):108-12. PubMed ID: 3648856
    [No Abstract]   [Full Text] [Related]  

  • 24. Guidelines for HIV antibody testing and post-test counseling. Colorado Department of Health.
    Colo Med; 1986 Dec; 83(21):365-6. PubMed ID: 3643078
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV antibody prevalence data derived from study of Massachusetts infants.
    Marwick C
    JAMA; 1987 Jul; 258(2):171-2. PubMed ID: 3474422
    [No Abstract]   [Full Text] [Related]  

  • 26. [Donors with positive antibodies against HIV virus in Red Cross blood banks].
    Franco E; Picazo J; Mazón C; Antich JL; Lafulla C; Ribó E; Contreras E
    Sangre (Barc); 1986; 31(6):775-6. PubMed ID: 3470958
    [No Abstract]   [Full Text] [Related]  

  • 27. [LAV/HTLV-III infection among homosexual men; prevalence, incidence and possible co-factors].
    de Wolf F; Coutinho RA; Goudsmit J; Krone W; Schellekens P; Danner S
    Ned Tijdschr Geneeskd; 1986 Nov; 130(48):2180-3. PubMed ID: 3643452
    [No Abstract]   [Full Text] [Related]  

  • 28. The prevalence of HTLV-III/LAV antibodies among intravenous drug users attending treatment programs in California: a preliminary report.
    Levy N; Carlson JR; Hinrichs S; Lerche N; Schenker M; Gardner MB
    N Engl J Med; 1986 Feb; 314(7):446. PubMed ID: 3456077
    [No Abstract]   [Full Text] [Related]  

  • 29. [HTLV-III monitoring in prostitutes in Vienna].
    Kopp W; Dangl-Erlach E
    Wien Klin Wochenschr; 1986 Oct; 98(20):695-8. PubMed ID: 3466478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of antibody to HTLV-III in homosexual men in Melbourne.
    Frazer IH; Mackay IR; Crapper RM; Gust ID; Sarngadharan MG
    Med J Aust; 1986 Mar; 144(5):276. PubMed ID: 3647228
    [No Abstract]   [Full Text] [Related]  

  • 31. Lymphadenopathic type of Kaposi's sarcoma in a Ugandan child seropositive for LAV/HTLV-III antibodies.
    Marquart KH; Müller HA; Hartter P; Oku JC; Ayuko WO
    J Trop Med Hyg; 1987 Apr; 90(2):93-4. PubMed ID: 3470530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
    Dietz B; Klose HJ; Gürtler L; Eberle J; Deinhardt F; Köhler-Vajta K; Peller P
    Thromb Haemost; 1986 Aug; 56(1):50-2. PubMed ID: 3095947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HTLV-III/LAV-antibody-positive soldiers in Berlin.
    James JJ; Morgenstern MA; Hatten JA
    N Engl J Med; 1986 Jan; 314(1):55-6. PubMed ID: 2999600
    [No Abstract]   [Full Text] [Related]  

  • 35. Data on human immunodeficiency virus (HIV) antibody testing among military recruits.
    James JJ; Morgenstern MA; Irby P
    Mil Med; 1987 Feb; 152(2):103-4. PubMed ID: 3103015
    [No Abstract]   [Full Text] [Related]  

  • 36. [Safety of immunoglobulins in view of the transmission of LAV/HTLV-III].
    Sugg U; Kaufmann R; Gürtler L; Schneider W
    Beitr Infusionther Klin Ernahr; 1987; 18():39-41. PubMed ID: 3326597
    [No Abstract]   [Full Text] [Related]  

  • 37. Seroepidemiologic screening for antibodies to LAV/HTLV-III in Sri Lanka, 1980-1982.
    Miller RA; Collier AC; Buchanan TM; Handsfield HH
    N Engl J Med; 1985 Nov; 313(21):1352-3. PubMed ID: 2997608
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of HTLV III/LAV envelope protein.
    Bicker U
    Nature; 1986 Nov 27-Dec 3; 324(6095):307. PubMed ID: 3466037
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening for HIV infection: risks, benefits, and the burden of proof.
    Barry MJ; Cleary PD; Fineberg HV
    Law Med Health Care; 1986 Dec; 14(5-6):259-67. PubMed ID: 3475517
    [No Abstract]   [Full Text] [Related]  

  • 40. Screening for antibodies to HIV (AIDS agent): application, interpretation and follow-up.
    Guarda NP; Peterson JZ
    Fla Nurse; 1986; 34(10):20-1. PubMed ID: 3466813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.